2020 Revenues ($USD) : $16,659,000,000
2020 R&D spend : $997,000,000
2020 Number of Employees : 40,216
Fiscal Year End : 12/31/2020
Key People : Kåre Schultz, president, CEO and director; Eric Drapé, executive vice president-global operations; Eli Kalif, CFO and executive vice president; Hafrun Fridriksdottir, executive VP-global R&D; Gianfranco Nazzi, EVP-growth markets commercial; Lori A. Queisser, SVP and global compliance officer; Brian E. Shanahan, vice president and deputy general counsel-transactions; Brendan O'Grady, EVP-North America commercial division; Richard Daniell, EVP-European commercial division; Sven Dethlefs, executive VP-global marketing and portfolio; Andrew Weil, chief accounting officer and SVP; Nir Baron, chief internal auditor and SVP; Mark Sabag, EVP, chief human resources officer and global communications and brand; David M. Stark, EVP, chief legal officer

Israel-based Teva Pharmaceuticals is developing drugs for the respiratory, migraine, headache, neurodegenerative condition, movement disorder and oncology therapeutic areas and makes generic medications. Diseases of focus include multiple sclerosis, Parkinson's disease, Huntington's disease and Tardive dyskinesia, as well as specialty therapies for chronic forms of leukemia and types of non-Hodgkin's lymphoma. –DK